<DOC>
	<DOC>NCT02629692</DOC>
	<brief_summary>Phase 1/2 study to determine safety, tolerability, pharmacokinetics and activity of K0706</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetic Study of K0706</brief_title>
	<detailed_description />
	<criteria>Willing and able to give written, and dated, informed consent Male or female aged â‰¥ 18 years Willing and able to comply with the scheduled visits Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Any major surgery, as determined by the Investigator, within 4 weeks of IMP administration Inability to undergo venipuncture and/or tolerate venous access Positive exclusion tests: urine pregnancy tests (if applicable), HIV, hepatitis B surface antigen, or hepatitis C virus Known or suspected history of significant drug abuse as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>